SMMT

$15.85

Post-MarketAs of Mar 17, 8:00 PM UTC

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$15.85
Potential Upside
5%
Whystock Fair Value$16.64
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific a...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-206.10%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
9.78

Recent News

Simply Wall St.
Mar 3, 2026

Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings

If you are wondering whether Summit Therapeutics is still priced mainly on its story or whether the current share price offers more fundamental value, this article will help unpack what the market might be implying. Over the past month the stock has returned 11.8%. Over one year the return sits at a 15.4% decline, and the three year return is very large, reflecting a move of more than 7x. Recent trading interest has been shaped by broad market attention on smaller biotech names and ongoing...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 3, 2026

Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the stocks with explosive growth potential. On February 23, Summit Therapeutics reported results for 2025 with a strong financial foundation, reporting ~$713.4 million in cash and no outstanding debt. While GAAP operating expenses for Q4 reached $225 million, this represented a decrease from the previous quarter. Conversely, non-GAAP […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 2, 2026

Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the development of ivonescimab in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). It’s undertaking multiregional Phase III clinical trials. In addition, the company has engaged GORTEC, […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.
GuruFocus.com
Feb 25, 2026

Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...

Summit Therapeutics Inc (SMMT) ends 2025 with a robust cash reserve and no debt, while advancing its clinical pipeline through strategic partnerships and increased R&D investments.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 24, 2026

Summit Therapeutics Inc. Q4 2025 Earnings Call Summary

Moby summary of Summit Therapeutics Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.